We are live on ! Find out more
AVLSA

Atlas Venture Life Science Advisors Portfolio holdings

AUM $790M
1-Year Est. Return 223.66%
This Fund
S&P 500
This Quarter Est. Return
+37.32%
1 Year Est. Return
+223.66%
3 Year Est. Return
+485.32%
5 Year Est. Return
10 Year Est. Return
AUM
$865M
AUM Growth
+$113M
Cap. Flow
-$95.8M
Cap. Flow %
-11.08%
Top 10 Hldgs %
100%
Holding
9
New
Increased
Reduced
4
Closed
1

Top Buys

No buys this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
KYMR icon
1
Kymera Therapeutics
KYMR
$8.28B
$363M 41.91%
4,659,874
-236,588
-5% -$16M
DYN icon
2
Dyne Therapeutics
DYN
$4.66B
$179M 20.64%
9,130,465
SION
3
Sionna Therapeutics
SION
$2.12B
$123M 14.24%
2,995,602
-619,925
-17% -$23.5M
IRON icon
4
Disc Medicine
IRON
$2.93B
$120M 13.9%
1,513,875
-628,742
-29% -$53.1M
DAWN
5
DELISTED
Day One Biopharmaceuticals
DAWN
$59.8M 6.91%
6,412,560
-17,697
-0.3% -$148K
KRRO icon
6
Korro Bio
KRRO
$154M
$9.11M 1.05%
1,137,149
QTTB icon
7
Q32 Bio
QTTB
$460M
$6.95M 0.8%
2,092,106
GBIO
8
DELISTED
Generation Bio
GBIO
$4.7M 0.54%
827,946
IMA
9
ImageneBio Inc
IMA
$65.2M
-377,814
Closed -$3.08M

Similar funds

Atlas Venture Life Science Advisors's Q4 2025 Portfolio in Review

As of Q4 2025, Atlas Venture Life Science Advisors held 9 positions worth $865M, up 15% from $753M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Atlas Venture Life Science Advisors withdrew a net $95.8M in Q4 2025, closing 1 position and reducing 4 holdings. Its most notable exit was ImageneBio Inc, an estimated $3.08M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Atlas Venture Life Science Advisors's biggest Q4 2025 reduction was Disc Medicine, cutting an estimated $53.1M.
  • Atlas Venture Life Science Advisors fully exited ImageneBio Inc in Q4 2025, selling an estimated $3.08M.
  • Atlas Venture Life Science Advisors's ten largest holdings make up 100% of its $865M portfolio in Q4 2025.
  • Atlas Venture Life Science Advisors opened 0 new positions and closed 1 in Q4 2025.
  • Atlas Venture Life Science Advisors's portfolio value rose 15% quarter-over-quarter to $865M.

Based on Atlas Venture Life Science Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.